The net profit of Sanofi, the pharmaceutical concern from France, grew in the third quarter by 10.3% and amounted to 2 billion 300 million euros. The indicator exceeded the experts' forecasts of 2 billion 140 million euros. Revenues for the quarter of 9 billion 400 million euros were also higher than market estimates of 9 billion 300 million euros. Its growth was 6.3%. Sales of the Genzyme division, which produces vaccines and drugs for the treatment of rare diseases, increased by 36.1%. Growth in revenue from the sale of vaccines was 8.2%. Good quarterly results allowed the company to raise the forecast for the current year for the second time in a year. Now, it expects earnings per share for the year to grow by 4-5%.
Commonwealth Bank of Australia forecasts central bank to keep policy rates steady16.09.2020
Zara's Inditex regains profit after three months due to the coronavirus outbreak11.09.2020
Initial unemployment claims seen higher than forecasts30.07.2020
Samsung expects upbeat chip demand, second quarter profit climbs